Global pharma major Lupin Limited on Friday announced that the United States Food and Drug Administration (U.S. FDA) has completed a GMP Inspection of its API manufacturing facility located at Dabhasa, India.
According to the company’s press statement, the inspection was conducted from April 8 to April 12, 2024, and concluded with no observations.
“We are pleased to announce the successful completion of the U.S. FDA inspection of our Dabhasa facility,” said Nilesh Gupta, Managing Director, Lupin. “This accomplishment underscores our unwavering dedication to maintaining the highest standards of quality and compliance in all aspects of our operations. This reaffirms our pursuit of excellence in delivering high-quality, affordable healthcare for all.”
